Drugs / Adjuvanted Sabin-IPV
last change May 2013 re-read 2 minutes ago

Adjuvanted Sabin-IPV

Developed for
poliomyelitis
Investigated by
Pauline Verdijk · World Health Organization

Trials 2 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01708720 Aug → Sep 2011 poliomyelitis Pauline Verdijk Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01709071 Feb → Nov 2012 poliomyelitis Pauline Verdijk Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Adjuvanted Sabin-IPV ClinicalTrials.gov intervention name — accepted as the source's own label NCT01708720
1

NCT01709071

Route Intramuscular Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg...” NCT01709071